Photo Charles Rosier, London UK | Partner at BTG Pactual

Charles Rosier, London UK | Partner at BTG Pactual

Charles Rosier, London UK | Partner at BTG Pactual

Charles Rosier's Work Experience

GMS (Goldman Sachs) is a leading investment bank that successfully operates around the world. As their Managing Director, he mainly focused on managing public assets. From 1997 to 2009, charles rosier (accéder au site) filled the role of Debt Capital Manager of SBC Warburg. He also worked at Lehman Brothers where he began his profession as an investment banker. Charles Rosier put in place five principles (Customer Focus, Global Thinking Presence, Long Term View, Meritocracy and Partnership and World-Class Governance) at BTG Pactual.

How Charles Rosier Was Educated

Charles Rosier took two years of additional classes in preparation for achieving further French qualifications. His profession began after he successfully finished his degree at ESCP Europe. Charles Rosier completed his secondary education in 1991 at Paris’s Fenelon Sainte-Marie.

The appointment of Charles Rosier at Lehman Brothers in the year 1996 was his very first step towards a brilliant future. Later on, he transferred to UBS Warburg as the manager for their Debt Capital Market Division in 1997. He became a member of BTG Pactual in August 2010. BTG Pactual is an investment bank in Latin America. He became a partner there. Charles Rosier deals with all the French-speaking markets like France, Belgium, as well as Quebec at UBS Warburg. Having 30 years of experience in working with international markets, BTG Pactual currently hires 2,500 personnel.

Health Related Projects

Charles Rosier was the primary investor of the project, for which a drug was being tested to cure stroke that causes damage to the spinal cord. The Mapreg Drug project was his first healthcare project. Charles Rosier invested capital in the company, which allowed them to conduct research and give him specific profit-share. When Baulieu and his co-workers were facing financial difficulties on developing a new drug, he financed them.

Nos articles